trial

Treatment for First-Episode Schizophrenia

NCTId NCT00000374
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 125 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2007-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
125 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
1998-09
Primary completion
2007-05
Eligibility
ALL · 16 Years · 40 Years

Interventions & indications

Drugs
OlanzapineRisperidone

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
The Zucker Hillside HospitalCollaborator

Investigators

1
Delbert G. Robinson, MDPrincipal Investigator

Sites

2 total
Glen Oaks, United StatesThe Bronx, United States

Facts & assertions

4 sourced
Enrollment
125
Phase
PHASE4
Primary Completion Date
2007-05
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Risperidone
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
National Institute of Mental Health (NIMH)
company
The Zucker Hillside Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Delbert G. Robinson, MD
person